The ICI therapy for the HAVCR2 has encouraged efficacy in treating advanced non-small cell lung cancer [60], hepatocellular carcinoma [61], etc. TIDE algorithm also revealed that CRC patients in the high-risk group were more sensitive to anti-PD-1 and anti-CTLA4 ICI therapy. The gene discussed is CTLA4; the disease is colorectal carcinoma.